JN

Johnson & JohnsonNYSE JNJ Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Sep, 2024

Last price

Market cap $B

401.99

Mega

Exchange

XNYS - New York Stock Exchange, Inc

JNJ Stock Analysis

JN

Neutral

Based on Eyestock quantitative analysis, JNJ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

85/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

125.9 %

Greatly undervalued

Market cap $B

401.99

Dividend yield

2.95 %

Shares outstanding

2 604.29 B

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in New Brunswick, New Jersey and currently employs 152,700 full-time employees. The firm is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The company operates through three segments: Consumer Health, Pharmaceutical and MedTech. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The MedTech segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.

View Section: Eyestock Rating